G2019S increases LRRK2 affinity for negatively charged, curved membranes (PI4P-enriched lysosomal membranes during swelling). This is not a kinase catalytic change but a localization change that amplifies local RAB10 phosphorylation. dSTORM microscopy can quantify membrane density differences between G2019S and WT.
## Mechanistic Overview
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## **Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) signaling cascade represents a critical node in neuroinflammation regulation, with its dysfunction fundamentally altering astrocyte-microgli
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
LysosomalNeuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
G2019S Amplifies Lysosomal Volume-Sensin
10/11
dimensions won
TREM2-Dependent Astrocyte-Microglia Cros
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.40
0.88
Evidence
0.45
0.80
Novelty
0.68
0.72
Feasibility
0.70
0.82
Impact
0.52
0.78
Druggability
0.48
0.65
Safety
0.58
0.58
Competition
0.72
0.70
Data
0.52
0.85
Reproducible
0.50
0.75
KG Connect
0.50
0.91
Score Breakdown
Dimension
G2019S Amplifies Lysosomal Vol
TREM2-Dependent Astrocyte-Micr
Mechanistic
0.400
0.880
Evidence
0.450
0.800
Novelty
0.680
0.720
Feasibility
0.700
0.820
Impact
0.520
0.780
Druggability
0.480
0.650
Safety
0.580
0.580
Competition
0.720
0.700
Data
0.520
0.850
Reproducible
0.500
0.750
KG Connect
0.500
0.911
Evidence
G2019S Amplifies Lysosomal Volume-Sensing Through Membrane M
No evidence citations yet
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
No evidence citations yet
Debate Excerpts
G2019S Amplifies Lysosomal Volume-Sensing Through
4 rounds · quality: 0.80
Theorist
# Therapeutic/Mechanistic Hypotheses Addressing LRRK2 Signal Amplification vs. Baseline Elevation
---
## Hypothesis 1: G2019S Acts as a Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependen...
Skeptic
# Critical Evaluation of LRRK2 Hypotheses
## Overview
The core question—whether G2019S increases signal amplification during lysosomal swelling versus merely elevating the baseline activity floor—re...
Domain Expert
# Feasibility Assessment: LRRK2 G2019S Signal Amplification vs. Baseline Elevation Hypotheses
## Executive Summary
The core mechanistic question—whether LRRK2 G2019S drives pathology through amplifi...
Based on the provided literature, TREM2 is a microglial surface receptor governing the disease-associated microglia (DAM) program. The TREM2 R47H loss-of-function variant increases Alzheimer's risk ~3...
Skeptic
The INVOKE-2 trial (AL002, TREM2 agonist) failed to meet primary endpoints in 2024. This raises questions about mechanism appropriateness, off-target effects from systemic activation, and whether amyl...
Domain Expert
TREM2 biology is highly stage-dependent. In early AD, TREM2 activation promotes amyloid clearance via DAM. In late AD, DAM may become senescent and contribute to chronic inflammation. Biomarker guidan...
Synthesizer
## TREM2 Showcase Synthesis
**Core verdict:** TREM2 is a legitimate but timing-sensitive AD target requiring biomarker-guided, stage-specific therapeutic modulation.
**Mechanistic consensus:** TREM2...